Literature DB >> 18707131

Hydrophobic interaction chromatography of soluble interleukin I receptor type II to reveal chemical degradations resulting in loss of potency.

Yuling Zhang1, Theresa Martinez, Brian Woodruff, Andy Goetze, Robert Bailey, Dean Pettit, Alain Balland.   

Abstract

A hydrophobic interaction chromatography method was developed to analyze recombinant soluble Interleukin 1 receptor type II (sIL-1R type II) drug substance and assess the stability of the drug under accelerated degradation studies. HIC resolved the degraded molecules into three peaks. A combination of several analytical techniques, including cyanogen bromide cleavage, reversed-phase chromatography, mass spectrometry, and N-terminal sequencing, were used to identify the origins of these peaks. We found that accelerated degradation resulted from three different events, deamidation and isomerization at asparagine 317 (Asn317), C-terminal cleavage, and aggregation. The iso-aspartate 317 (iso-Asp317)-containing species were shown to elute in HIC peak I and the Asp317-containing species in HIC peak II, respectively. Deamidation-isomerization to iso-Asp317, but not deamidation to Asp317, resulted in altered retention time on HIC companied by loss of potency, presumably by introducing a significant conformational change. CNBr C-terminal analysis showed that the inactive HIC peak I consisted of sIL-1R type II with "large" C-terminal truncations of 13 or 14 amino acids, whereas the active HIC peak II contained C-terminally full length and "small" C-terminal clips of two amino acids. Molecular modeling indicates that the short loop D317-S320, in the third domain of IL-1R type II, has a crucial impact on the stability of the molecule.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18707131     DOI: 10.1021/ac800928z

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  5 in total

1.  Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation.

Authors:  Sejal Gandhi; Da Ren; Gang Xiao; Pavel Bondarenko; Christopher Sloey; Margaret Speed Ricci; Sampathkumar Krishnan
Journal:  Pharm Res       Date:  2011-08-16       Impact factor: 4.200

2.  Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule.

Authors:  David Ouellette; Chris Chumsae; Anca Clabbers; Czeslaw Radziejewski; Ivan Correia
Journal:  MAbs       Date:  2013-04-22       Impact factor: 5.857

3.  Microfluidic chips with reversed-phase monoliths for solid phase extraction and on-chip labeling.

Authors:  Pamela N Nge; Jayson V Pagaduan; Ming Yu; Adam T Woolley
Journal:  J Chromatogr A       Date:  2012-09-01       Impact factor: 4.759

4.  A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies.

Authors:  Zhengqi Zhang; Yuetian Yan; Shunhai Wang; Ning Li
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

5.  Identification of critical chemical modifications and paratope mapping by size exclusion chromatography of stressed antibody-target complexes.

Authors:  Pavel Bondarenko; Andrew C Nichols; Gang Xiao; Rachel Liuqing Shi; Pik Kay Chan; Thomas M Dillon; Fernando Garces; David J Semin; Margaret S Ricci
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.